TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“ Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has filed a new provisional patent application in support of its ongoing drug candidate programs. The application discloses novel compositions which are expected to have improved pharmacokinetic profiles while…


Previous articlePsychedelic Science 101: What are Psychedelic Drugs?
Next articleWesana Health Expands Research Leadership Team with Mark Wingertzahn, PhD as Chief Scientific Officer